Otsuka Pharmaceutical's Centanafadine Phase 3b Trial Meets Primary Endpoint Ahead of FDA Approval
Addressing Unmet Needs in Adult ADHD Patients with Comorbid Anxiety
Otsuka Pharmaceutical's centanafadine, a triple reuptake inhibitor (SNDRI) and a novel ADHD drug candidate, has successfully met the primary endpoint in a Phase 3b trial involving adult patients with comorbid anxiety. Approximately 33% of all ADHD patients also suffer from anxiety; however, previous Phase 3 trials excluded these patients due to concerns about drug interactions, limiting the ability to gather real-world data. This trial demonstrates robust therapeutic efficacy in a complex patient population with high prescription rates, establishing a strong scientific basis for expanding the drug's prescription base after commercialization.
Improved Adult Assessment Scale Scores and Reduced Anxiety Symptoms
In the Phase 3b trial, which included a total of 315 adult patients, the centanafadine group showed a reduction of 18.5 points in the Adult ADHD Self-Report Scale (AISRS) at week 8, demonstrating a statistically significant placebo-adjusted improvement of 5.87 points compared to the placebo group (12.6-point reduction). Furthermore, the Hamilton Anxiety Rating Scale (HAM-A), a secondary endpoint, showed an additional reduction of 1.92 points compared to the placebo group, indicating a statistically significant improvement in comorbid anxiety symptoms. This demonstrates a differentiated clinical value by overcoming the potential for increased anxiety symptoms, a common side effect of stimulant-based treatments, and enabling the management of complex symptoms with a single drug.
FDA Approval Decision Imminent and Potential for Initial Launch Delay
The U.S. Food and Drug Administration (FDA) has accepted Otsuka Pharmaceutical's New Drug Application (NDA) for centanafadine for pediatric, adolescent, and adult use and is conducting a priority review. The Prescription Drug User Fee Act (PDUFA) target action date for final approval is July 24, 2026. Otsuka Pharmaceutical has already established a commercial infrastructure, including a dedicated sales force; however, if the U.S. Drug Enforcement Administration (DEA) conducts a scheduling review, the launch date may be delayed by approximately three months. Nevertheless, the positive Phase 3b trial data released just before regulatory approval is expected to increase the likelihood of regulatory approval and serve as a key asset for immediate use in initial market entry marketing.
Market Shift in Non-Stimulant Segment and Diversification of Competitive Landscape
The global ADHD treatment market is projected to grow rapidly from approximately $15 billion in 2023 to $25 billion in 2032. Otsuka Pharmaceutical acquired the pipeline by acquiring Neurovance for $250 million in 2017. The existing market is divided between stimulants with a high risk of abuse, such as methylphenidate, and non-stimulants such as atomoxetine and viloxazine ER. Centanafadine, a non-stimulant, regulates dopamine, norepinephrine, and serotonin through a unique mechanism, providing stimulant-level efficacy and non-stimulant safety, positioning it as a viable alternative in the market.
The success of the Phase 3b trial for centanafadine is significant because it allows Otsuka Pharmaceutical to capture a portion of the ADHD patient population with comorbid anxiety, which accounts for 33% of all ADHD patients, thereby securing a differentiated prescription position as a latecomer. In the short term, it can lead to early gains in market share by demonstrating superior clinical data compared to other non-stimulant drugs, such as atomoxetine and viloxazine ER, in the medical field immediately after the expected FDA approval on July 24, 2026. In the medium to long term, it is expected to absorb a large portion of the demand from patients who avoid stimulant treatments due to their side effects, such as anxiety, in the $15 billion global ADHD market. Furthermore, from the perspective of Otsuka Pharmaceutical's R&D return on investment and the remaining milestone payments included in the $250 million Neurovance acquisition agreement, securing this clinical data will optimize the asset value.